New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: A randomized controlled trial (EDITION 3)

Diabetes, Obesity and Metabolism

Volumn 17, Issue 4, 2015, Pages 386-394

  Bolli, G B ^a   Riddle, M C ^b   Bergenstal, R M ^c   Ziemen, M ^d   Sestakauskas, K ^e   Goyeau, H ^f   Home, P D ^g  

^a UNIVERSITY OF PERUGIA   (Italy)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c INTERNATIONAL DIABETES CENTER   (United States)

^d SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^e SANOFI   (France)

^f EXPERIS IT   (France)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Basal insulin analogues; Basal insulin initiation; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLINIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN GLARGINE 100; INSULIN GLARGINE 300; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; DELAYED RELEASE FORMULATION; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN INJECTION PEN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PATIENT SATISFACTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; TEST STRIP; TREATMENT DURATION; WEIGHT CHANGE; WEIGHT GAIN; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; AGED; ANALYSIS; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DRUG MONITORING; DRUG RESISTANCE; EUROPE; HYPERGLYCEMIA; JAPAN; NORTH AMERICA; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; RISK; SUBCUTANEOUS DRUG ADMINISTRATION; THERAPEUTIC USE;

ADMINISTRATION, ORAL; AGED; BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; DRUG RESISTANCE; EUROPE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN GLARGINE; JAPAN; MALE; MIDDLE AGED; NORTH AMERICA; RISK; WEIGHT GAIN;

EID: 84924731879     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12438     Document Type: Article

References (25)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
2. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005; 28: 2543-2545.
3. Nam S, Chesla C, Stotts NA, Kroon L, Janson SL. Factors associated with psychological insulin resistance in individuals with type 2 diabetes. Diabetes Care 2010; 33: 1747-1749.
4. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med 2012; 29: 682-689.
5. Kunt T, Snoek FJ. Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract 2009; 63(Suppl. 164): 6-10.
6. Grunberger G. The need for better insulin therapy. Diabetes Obes Metab 2013; 15(Suppl. 1): 1-5.
7. ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR etal. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-328.
8. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
9. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008; 371: 1073-1084.
10. Davies M, Lavalle-Gonzalez F, Storms F, Gomis R. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diabetes Obes Metab 2008; 10: 387-399.
11. Aschner P, Chan J, Owens DR et al. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet 2012; 379: 2262-2269.
12. -1. Diabetes Care 2014; DOI: 10.2337/dc14-0006 (EPub ahead of print).
13. Riddle MC, Bolli GB, Zieman M, Meuhlen-Bartmer I, Bizet F, Home PD. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care 2014; 37: 2755-2762.
14. Yki-Järvinen H, Bergenstal RM, Ziemen M et al. New insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes usingoral agents and basal insulin: glucose control and hypoglycemia in a 6-monthrandomized controlled trial (EDITION 2). Diabetes Care 2014; 37: 3235-3243.
15. WHO. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization, 1999.
16. ADA Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245-1249.
17. Bradley C. The diabetes treatment satisfaction questionnaire: DTSQ. In: Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Hove: Psychology Press, 1994; 111-132.
18. Bradley C, Lewis KS. Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabet Med 1990; 7: 445-451.
19. Lewis KS, Bradley C, Knight G, Boulton AJ, Ward JD. A measure of treatment satisfaction designed specifically for people with insulin-dependent diabetes. Diabet Med 1988; 3: 235-242.
20. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
21. Irvine A, Cox DJ, Gonder-Frederick L. The fear of hypoglycemia scale. In: Handbook of Psychology and Diabetes: A Guide to Psychological Measurement and Diabetes Research and Practice. Hove: Psychology Press, 1994; 133-155.
22. Tschope D, Bramlage P, Binz C, Krekler M, Deeg E, Gitt AK. Incidence and predictors of hypoglycaemia in type 2 diabetes - an analysis of the prospective DiaRegis registry. BMC Endocr Disord 2012; 12: 23.
23. Yki-Järvinen H, Kauppinen-Makelin R, Tiikkainen M, Vähätalo M, Virtamo H, Nikkilä K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49: 442-451.
24. Home PD, Bergenstal R, Riddle MC, Ziemen M, Rojeski M, Espinasse M etal. Glycemic control and hypoglycemia with new insulin glargine 300 U/mL in people with T1DM (EDITION 4). Diabetes 2014; 63(Suppl. 1A): LB19.
25. Jørgensen KH, Hansen AK, Buschard K. Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs. Diabetes Res Clin Pract 2000; 50: 161-167.